Can we jump from cross-sectional to dynamic interpretations of networks implications for the network perspective in psychiatry FM Bos, E Snippe, S De Vos, JA Hartmann, CJP Simons, ... Psychotherapy and psychosomatics 86 (3), 175-177, 2017 | 162 | 2017 |
HowNutsAreTheDutch (HoeGekIsNL): A crowdsourcing study of mental symptoms and strengths LVD Krieke, BF Jeronimus, FJ Blaauw, RBK Wanders, AC Emerencia, ... International journal of methods in psychiatric research 25 (2), 123-144, 2016 | 145 | 2016 |
A transdiagnostic network approach to psychosis JTW Wigman, S de Vos, M Wichers, J van Os, AA Bartels-Velthuis Schizophrenia bulletin 43 (1), 122-132, 2017 | 101 | 2017 |
An investigation of emotion dynamics in major depressive disorder patients and healthy persons using sparse longitudinal networks S De Vos, KJ Wardenaar, EH Bos, EC Wit, MEJ Bouwmans, P De Jonge PLoS One 12 (6), e0178586, 2017 | 72 | 2017 |
Decomposing the heterogeneity of depression at the person-, symptom-, and time-level: latent variable models versus multimode principal component analysis S de Vos, KJ Wardenaar, EH Bos, EC Wit, P De Jonge BMC Medical Research Methodology 15, 1-10, 2015 | 37 | 2015 |
A systematic literature review and meta‐analysis of community pharmacist‐led interventions to optimise the use of antibiotics M Lambert, CCH Smit, S De Vos, R Benko, C Llor, WJ Paget, K Briant, ... British journal of clinical pharmacology 88 (6), 2617-2641, 2022 | 23 | 2022 |
HowNutsAreTheDutch: personalized feedback on a national scale F Blaauw, L van der Krieke, E Bos, A Emerencia, BF Jeronimus, ... 2014 AAAI Fall Symposium Series, 2014 | 17 | 2014 |
Sex disparities in the effect of statins on lipid parameters: The PharmLines Initiative NB Hunt, JE Emmens, S Irawati, S de Vos, JHJ Bos, B Wilffert, E Hak, ... Medicine 101 (2), e28394, 2022 | 14 | 2022 |
Chronic use of hydrochlorothiazide and risk of skin cancer in caucasian adults: a pharmlines initiative inception cohort study MS Haisma, N Greven, M Logendran, J Bos, BVD Vegt, B Horváth, ... Acta dermato-venereologica 103, adv3933, 2023 | 13 | 2023 |
Toward evidence‐based medical statistics: a Bayesian analysis of double‐blind placebo‐controlled antidepressant trials in the treatment of anxiety disorders R Monden, S de Vos, R Morey, EJ Wagenmakers, P de Jonge, AM Roest International Journal of Methods in Psychiatric Research 25 (4), 299-308, 2016 | 13 | 2016 |
HowNutsAreTheDutch ((HoeGekIsNL): A crowdsourcing study of mental symptoms and strengths. International Journal of Methods in Psychiatric Research, 25 (2), 123–144 L Van Der Krieke, BF Jeronimus, FJ Blaauw, RBK Wanders, ... | 9 | 2016 |
Repurposed drug studies on the primary prevention of SARS-CoV-2 infection during the pandemic: systematic review and meta-analysis G Zhou, S Verweij, MJ Bijlsma, S de Vos, KO Rengerink, AMG Pasmooij, ... BMJ open respiratory research 10 (1), e001674, 2023 | 6 | 2023 |
Subtyping psychological distress in the population: a semi-parametric network approach S de Vos, S Patten, EC Wit, EH Bos, KJ Wardenaar, P de Jonge Epidemiology and Psychiatric Sciences 29, e36, 2020 | 6 | 2020 |
In utero antidepressant exposure not associated with ADHD in the offspring: A case control sibling design CAM Hartwig, R Robiyanto, S de Vos, JHJ Bos, EP van Puijenbroek, ... Frontiers in Pharmacology 13, 1000018, 2022 | 4 | 2022 |
Antidepressant use during pregnancy and development of preeclampsia: A focus on classes of action and specific transporters/receptors targeted by antidepressants YH Tran, HK Huynh, MM Faas, S de Vos, H Groen Journal of Psychiatric Research 146, 92-101, 2022 | 4 | 2022 |
Targeting the beta-2-adrenergic receptor and the risk of developing Alzheimer’s disease: A retrospective inception cohort study DR Hutten, JHJ Bos, S de Vos, E Hak Journal of Alzheimer's Disease 87 (3), 1089-1101, 2022 | 4 | 2022 |
Sex disparities in treatment patterns after metformin initiation among patients with type 2 diabetes mellitus MP Oktora, S de Vos, ST de Vries, E Hak, P Denig Pharmacoepidemiology and Drug Safety 32 (12), 1395-1405, 2023 | 3 | 2023 |
Role of traditional cardiovascular risk factors after initiation of statin therapy: a pharmlines inception cohort study D Steenhuis, S De Vos, J Bos, E Hak Cardiovascular therapeutics 2022 (1), 6587165, 2022 | 3 | 2022 |
Risk factors for drug-treated major adverse cardio-cerebrovascular events in patients on primary preventive statin therapy: a retrospective cohort study D Steenhuis, S de Vos, JHJ Bos, E Hak Preventive Medicine Reports 34, 102258, 2023 | 2 | 2023 |
Association between adherence to statin therapy and low-density lipoprotein cholesterol (LDL-c) response in first-time users of standard-dose and low-dose statins: the … S Irawati, JE Emmens, S de Vos, JHJ Bos, RA de Boer, E Hak Current Medical Research and Opinion 38 (1), 1-6, 2022 | 2 | 2022 |